Showing results (171-180 of 202) with videos related to
Sort By:
Pageof 21
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 6, 2026
Efficacy and Genomic Analysis of HER2-Mutant Metastatic Triple-Negative Breast Cancer Treated with Neratinib Alone or with Trastuzumab in the SUMMIT Basket TrialKomal Jhaveri, Lisa D Eli, Sara A Hurvitz, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 29, 2024
Final Results From the Randomized Phase III ASCENT Clinical Trial in Metastatic Triple-Negative Breast Cancer and Association of Outcomes by Human Epidermal Growth Factor Receptor 2 and Trophoblast Cell Surface Antigen 2 ExpressionAditya Bardia, Hope S Rugo, Sara M Tolaney, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 17, 2021
Phase I Study of Entinostat and Nivolumab with or without Ipilimumab in Advanced Solid Tumors (ETCTN-9844)Evanthia T Roussos Torres, Christine Rafie, Chenguang Wang, et al.Therapeutic Advances in Medical Oncology|December 28, 2023
Phase Ib study of HSP90 inhibitor, onalespib (AT13387), in combination with paclitaxel in patients with advanced triple-negative breast cancerNicole O Williams, Dionisia Quiroga, Courtney Johnson, et al.Breast Cancer Research and Treatment|April 25, 2019
Examination and prognostic implications of the unique microenvironment of breast cancer brain metastasesMaria J Sambade, Grace Prince, Allison M Deal, et al.Breast (Edinburgh, Scotland)|January 26, 2023
Final findings from the CONTROL trial: Strategies to reduce the incidence and severity of neratinib-associated diarrhea in patients with HER2-positive early-stage breast cancerArlene Chan, Manuel Ruiz-Borrego, Gavin Marx, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 27, 2015
Sensitive Detection of Mono- and Polyclonal ESR1 Mutations in Primary Tumors, Metastatic Lesions, and Cell-Free DNA of Breast Cancer PatientsPeilu Wang, Amir Bahreini, Rekha Gyanchandani, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 21, 2009
Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancerNancy U Lin, Véronique Diéras, Devchand Paul, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 17, 2012
Analysis of Fcγ receptor IIIa and IIa polymorphisms: lack of correlation with outcome in trastuzumab-treated breast cancer patientsSara A Hurvitz, David J Betting, Howard M Stern, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 19, 2012
Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with node-positive, human epidermal growth factor receptor 2-positive breast cancerEdward H Romond, Jong-Hyeon Jeong, Priya Rastogi, et al.Pageof 21